Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial
Sign Up to like & getrecommendations! Published in 2017 at "NPJ Primary Care Respiratory Medicine"
DOI: 10.1038/s41533-017-0032-z
Abstract: Asthma mortality surveys report delays in seeking medical review and overuse of beta-agonist therapy as factors contributing to a fatal outcome. However, the strength of these associations is limited because many asthma deaths are unwitnessed.… read more here.
Keywords: beta agonist; maintenance; medical review; review ... See more keywords
Effectiveness of Spacer Devices on Preventing Undesirable Cardiovascular Effects of Inhaled Salbutamol.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of aerosol medicine and pulmonary drug delivery"
DOI: 10.1089/jamp.2019.1591
Abstract: Background: Currently, there are no regulatory guidelines indicating spacer devices/valved holding chamber (VHC) should be used routinely during pulmonary function tests, and few studies evaluated if spacer devices reduce beta-agonist bronchodilators' side effects. Methods: A… read more here.
Keywords: beta agonist; spacer; spacer devices; agonist bronchodilators ... See more keywords
Use of intravenous short-acting beta-2 agonist in addition to standard first-line treatment versus placebo in children and adolescents with acute severe asthma exacerbation: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2025 at "Archives of Disease in Childhood"
DOI: 10.1136/archdischild-2024-327452
Abstract: Importance The role of intravenous short-acting beta-2 agonist (SABA) in acute asthma in childhood is unclear. Objectives To assess the safety and efficacy of intravenous SABA versus placebo for acute asthma. Data selection and extraction… read more here.
Keywords: versus placebo; intravenous short; intravenous saba; beta agonist ... See more keywords